- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04591067
Physical Capacity Among Patients Treated With Periacetabular Osteotomy for Hip Dysplasia: a Cross-sectional Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hip dysplasia is a common disease both worldwide and among the Danish population. The disease is characterized by a shallow and oblique acetabulum, resulting in insufficient coverage of the femoral head. The abnormalities of the dysplastic hip joint lead to altered biomechanical adaptations, highly affecting the physical capacity of patients. Studies have shown that patients with hip dysplasia experience reduced muscle strength and gait abnormalities, when compared to healthy controls.
Each year, approximately 200 Danes with hip dysplasia are treated with periacetabular osteotomy (PAO). As the preferable joint-preserving surgical treatment for younger patients with symptomatic hip dysplasia, the PAO reduces prevalence of muscle-tendon-related pain and improves hip and groin related patient-reported outcome measures (PROMs). By extension, studies report a hip survival rate of approximately 75% 12 years following PAO.
However, little is known about objective measures of physical capacity following PAO. Despite reducing muscle-tendon-related pain and improving PROMs, gait adaptations still remain and studies report no improvements in muscle strength, nor in the physical activity profile, 1 year following treatment with PAO. Thus, the field calls for research aiming to identify parameters of impaired physical capacity in patients treated with PAO. Thorough knowledge of physical capacity in these patients may contribute to the establishment of a science-based rehabilitation strategy, potentially improving physical activity, function, work capacity and quality of life.
The primary aim of this study is to analyse and identify parameters of impaired physical capacity in patients with hip dysplasia 1-5 years following treatment with PAO. Gait function, defined as peak hip extension angle and peak hip flexor moment, is chosen as the primary outcome, due to previously shown correlations between the extent of gait impairments and the Copenhagen Hip and Groin Outcome Score (HAGOS).
As recommended by the International Hip-related Pain Research Network (IHiPRN), measurements of physical capacity in patients with hip-related pain should include: clinical measures, laboratory-based measures, measures of physical activity and return to physical activity. Secondary outcomes of this study are: muscle activity during level walking and walking with inclination, endurance and pain during walking, range of motion (ROM), muscle strength, hip and muscle-tendon-related pain, radiographic measures and PROMs (present level of physical activity and sports & activity level prior to and after treatment with PAO).
We hypothesise that patients with the lowest scores of HAGOS subscales pain and sport/recreation will have the lowest physical capacity, measured as: gait impairments, reduced muscle strength and prevalence of muscle-tendon-related pain.
This is a cross-sectional study.
Thirty subjects from across the country, aged 18-40 years, who have undergone a PAO for hip dysplasia within the last 1-5 years, will be included in the study.
All testing will be performed at Copenhagen University Hospital, Hvidovre.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hvidovre
-
Copenhagen, Hvidovre, Denmark, 2650
- Department of Orthopedic Surgery, Copenhagen University Hospital Amager-Hvidovre, Hvidovre, Denmark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
Subjects will be recruited through social media from two specific closed-member facebook groups for patients with hip dysplasia. Permission for recruiting through social media was granted by The Danish Data Protection Agency along with permission for the handling of personal data (P-2020-261).
Description
Inclusion Criteria:
- Age 18 to 40 years
- BMI < 30
- Primary diagnosis of ipsilateral or bilateral hip dysplasia
- Treated with PAO for hip dysplasia unilaterally or bilaterally within 1-5 years
Exclusion Criteria:
- Retroverted acetabulum (positive posterior wall sign and ischial spine sign) treated with reversed PAO
- Total Hip Arthroplasty (THA)
- Pain management with analgesics or other medication affecting muscle function and perception of pain
- A need for walking aids to be able to walk freely
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hip Dysplasia group
Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
|
This cross-sectional study will involve evaluation of physical capacity by assessment of:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait function
Time Frame: Baseline
|
Peak hip extension angle and peak hip flexor moment
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait function following fatigue
Time Frame: Baseline
|
Peak hip extension angle and peak hip flexor moment following a 6-Minute walk test
|
Baseline
|
Muscle activity
Time Frame: Baseline
|
Muscle activity of hip specific muscles during level walking and walking with inclination
|
Baseline
|
Maximal voluntary isometric hip muscle force
Time Frame: Baseline
|
Adduction, abduction, flexion and extension
|
Baseline
|
Hip and muscle-tendon-related groin pain
Time Frame: Baseline
|
FADIR and FABER, modified standardized clinical entity approach
|
Baseline
|
Hip specific patient reported outcome measures (PROMs)
Time Frame: Baseline
|
Present level of physical activity and sports & activity level prior to and after treatment with PAO
|
Baseline
|
Collaborators and Investigators
Investigators
- Study Director: Per Hölmich, Professor, dr.med., Sports Orthopedic Research Center - Copenhagen (SORC-C), Copenhagen University Hospital Amager-Hvidovre, Hvidovre, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20006975
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Joint Diseases
-
Zyga Technology, Inc.TerminatedSacroiliac Joint DysfunctionUnited States
-
Surgalign Spine TechnologiesUnknownSacroiliac Joint DysfunctionUnited States
-
Sahmyook UniversityRecruitingMusculoskeletal Manipulations | Chronic Instability of Joint | Ankle JointKorea, Republic of
-
Universidad Politecnica de MadridCompleted
-
Biruni UniversityCompletedHypermobility, JointTurkey
-
Foundation University IslamabadRecruitingSacroiliac JointPakistan
-
Riphah International UniversityCompletedInstability, JointPakistan
-
Gdansk University of Physical Education and SportCompleted
-
Smith & Nephew Orthopaedics AGCompletedInstability, JointSpain, Italy, United States, Denmark, Finland, United Kingdom
-
Medical Corps, Israel Defense ForceAriel UniversityUnknownChronic Instability of JointIsrael
Clinical Trials on Testing of physical capacity
-
Hospital Universitario La FeUnknown
-
PulmOne Advanced Medical Devices, Ltd.CompletedTLC in Patients With and Without Respiratory System DiseaseIsrael
-
GULIN FINDIKOGLUCompletedDiabetes Mellitus, Type 2 | Gait Disorder, SensorimotorTurkey
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Graft Versus Host DiseaseUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Primary Pelvic NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Lung Non-Small Cell CarcinomaUnited States
-
The Opole University of TechnologyCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States